Early progress is a reliable predictor of ultimate outcome
Current Opinion in Biotechnology, 54 , 114120
baseline 247.8 lb (Wegovy HD and placebo), 256.9 lb (Wegovy 2.4 mg), and BMI 39.9 kg/m 2 (N=1,407, randomized 5:1:1 to Wegovy HD injection 7.2 mg, Wegovy injection 2.4 mg, or placebo)
Are there alternative options that may work better long-term
This biological process cannot be meaningfully hastened through dietary changes, increased fluid intake, exercise, or any over-the-counter supplements
Understanding the full spectrum of skin reactions associated with GLP-1 therapy helps clinicians distinguish between benign findings and those that require closer monitoring or discontinuation